DOCSLIB.ORG

List of Basic Essential Medicines Ministry of Health Seychelles 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Basic Essential Medicines Ministry of Health Seychelles 2010 LIST OF BASIC ESSENTIAL MEDICINES MINISTRY OF HEALTH SEYCHELLES 2010 Drugs that should never be out of stock Should have minimum of 90-day stock Shortage could create major reactions ANAESTHETICS General Anaesthetics HALOTHANE, 250 ML BOTTLE ISOFLURANE 100ML ETOMIDATE INJECTION 2MG /1ML, 10ML AMPOULE KETAMINE 10MG ML 20ML NITROUS OXIDE OXYGEN, COMPRESSED AIR PROPOFOL INJECTION 1% 10MG/ML THIOPENTONE SODIUM INJECTION, 500MG/VIAL Local Anaesthetics BUPIVACAINE INJECTION 0.5%, 10ML AMPOULE BUPIVACAINE HEAVY INJECTION 5MG & 80MG/ML GLUCOSE, 4ML AMPOULE) LIGNOCAINE HCL INJECTION 2%, 30ML BOTTLE LIGNOCAINE 2% + ADRENALINE 1:200000 20ML LIGNOCAINE 2% + ADRENAINE 1: 80000 1.8ML DENTAL CARTRIDGES LIGNOCAINE METERED HCL SPRAY 10MG /DOSE, 800 DOSES UNIT ETHYL CHLORIDE SPRAY PRILOCAINE 4% DENTAL CARTRIDGE Preoperative Medication and Sedation for short-term Procedures ATROPINE INJECTION 1MG/ML, 1ML AMPOULE FENTANYL INJECTION 50 MCG/ML, 2ML AMPOULE MIDAZOLAM INJECTION 5MG/ML, 3ML AMPOULE MORPHINE SULPHATE INJECTION 10MG/ML, 10ML AMPOULE ANALGESICS, ANTIPYRETICS Non-opioids ASPIRIN TABLET 300MG DICLOFENAC SODIUM TABLET 100MG SR DICLOFENAC SODIUM INECTION 25MG/ML 3ML AMPOULES IBUPROFEN TABLET 400MG INDOMETHACIN CAPSULE 25MG PARACETAMOL TABLET 500MG PARACETAMOL ELIXIR 120MG/5ML, 100ML BOTTLE PARACETAMOL SUPPOSITORIES 125MG ; 250MG ; 1G (C) PROPACETAMOL INJECTION 500MG & 1G/VIAL Page 1 Opioids CODEINE PHOSPHATE TABLET 30MG CODEINE PHOSPHATE SYRUP FENTANYL INJECTION 50MCG /ML, 2ML AMPOULE MORPHINE ORAL SOLUTION 2MG/ML (300ML BOTTLE) MORPHINE SULPHATE INJECTION 10MG /ML, 1ML AMPOULE MORPHINE SULPHATE S/R TABLET 10MG & 30MG PETHIDINE HCL INJECTION 50MG /ML, 1.1ML AMPOULE TRAMADOL HCL TABLET 50MG (C) Medicines to treat Gout ALLOPURINOL TABLET 100MG COLCHICINE TABLET 1MG Disease Modifying Agents used in Rheumatic Disorders AZATHIOPRINE TABLET 50MG ( C) METHOTREXATE TABLET 2.5MG ( C) SULPHASALAZINE TABLET 500MG ( C ) ANTIALLERGICS AND MEDICINES USED IN PROPHYLAXIS ADRENALINE INJECTION 1MG/ML, 1ML AMPOULE CETIRIZINE TABLET 10MG ( C) CETIRIZINE SYRUP 5MG/5ML ( C) CHLORPHENIRAMINE TABLET 4MG CHLORPHENIRAMINE SYRUP 2MG/5ML CHLORPHENIRAMINE INJECTION 10MG/ML 1ML HYDROCORTISONE POWDER FOR INJECTION, 100MG HYDROXYZINE TABLET 25MG ( C) PREDNISOLONE TABLET 5MG PROMETHAZINE HCL INJECTION 25MG /ML, 1ML AMPOULE ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING General CHARCOAL, ACTICVATED POWDER, 50G IPECACUANHA SYRUP 7%, 50ML Specific ACETYLCYSTEINE INJECTION 200MG/ML, 10ML AMPOULE ATROPINE INJECTION 1MG/ML, 1ML AMPOULE DESFERRIOXAME INJECTION 500MG/VIAL FLUMAZENYL 100MCG/ML 5ML AMPOULE NALOXONE INJECTION O.4MG/1ML & 0.04MG/2ML AMPOULE PRALIDOXIME INJECTION 200MG/ML, 5ML AMPOULE Page 2 ANTIEPILEPTICS/ANTICONVULSANTS CARBAMAZEPINE TABLET 200MG CARBAMAZEPINE SYRUP 100MG/5ML 100ML BOTTLE (C ) CLONAZEPAM TABLET 2MG (C) DIAZEPAM INJECTION 10MG LAMOTRIGINE 200MG TAB ( C) LEVIRACETAM 500MG TABLET (C ) MAGNESIUM SULPHATE INJECTION 500MG/ML PHENOBARBITONE TABLET 30MG SCORED PHENOBARBITONE INJECTION 200 MG/ML, 1ML AMPOULE PHENYTOIN INJECTION 50MG /ML, 5ML AMPOULE PHENYTOIN TABLET 100MG SODIUM VALPROATE SYRUP 200MG /5ML, 300ML BOTTLE SODIUM VALPROATE TABLET 200MG EC ANTI-INFFECTIVE MEDICINES Anthelmintic Medicines MEBENDAZOLE TABLET 100MG LEVAMISOLE SYRUP 40MG /5ML, 5ML BOTTLE THIABENDAZOLE TABLET 500MG Antiamoebic Medicines METRONIDAZOLE TABLET 200MG METRONIDAZOLE INJECTION 5MG /ML, 100ML BOTTLE DILOXANIDE TABLET 500MG Antibacterial Medicines Penicillins BENZATHINE PENICILLIN INJECTION 1.44G (1.2MU/VIAL) BENZYL PENICILLIN INJECTION 600MG (1.0MU/VIAL) PHENOXYMETHYLPENICILLIN TABLET 250MG PHENOXYMETHYLPENICILLIN SYRUP 125MG/5ML, 100ML BOTTLE AMOXYCILLIN CAPSULE 250MG CO-AMOXYCLAV CAPS 500MG/ 125MG ( C) AMOXYCILLIN SYRUP 125MG /5ML; 250MG/5ML 100ML BOTTLE CO-AMOXYCLAV SYRUP 250MG/62.5MG /5ML 100ML ( C) AMOXYCILLIN INJECTION 500MG & 1G VIAL CO-AMOXYCLAV INJ 1G/200MG/VIAL CLOXACILLIN CAPSULE 250MG CLOXACILLIN SYRUP 125MG /5ML, 100ML BOTTLE CLOXACILLIN INJECTION 500MG /VIAL Page 3 Other Antibacterial Medicines AMIKACIN INJECTION 250MG /2ML & 100MG/2ML VIAL (RESERVE) CEFTAZIDIME INECTION 1G VIAL (RESERVE) CEFTRIAXONE IV INJECTION 250MG /1G IV VIAL (RESERVE) CEFAZOLIN 1G VIAL IV CEPHALEXIN CAPSULE 250MG CEPHALEXIN SYRUP 250MG /5ML, 100ML BOTTLE CEFIXIME 400MG TABLET CIPROFLOXACIN TABLET 250MG & 1G SR (C ) CIPROFLOXACIN 200MG/100ML IV (RESERVE) CLINDAMYCIN CAPSULE 150MG ( C) CLARYTHROMYCIN 500MG CAPS (C ) CO-TRIMOXAZOLE INJECTION 96MG/ML, 5ML AMPOULE CO-TRIMOXAZOLE 480MG TABLET CO-TRIMOXAZOLE SYRUP 240MG/5ML 100ML DOXYCYCLINE CAPSULES 100MG ERYTHROMYCIN SYRUP 125MG /5ML, 100ML BOTTLE ERYTHROMYCIN TABLES 250MG GENTAMYCIN INJECTION 40MG /ML, 2ML VIAL GENTAMYCIN INJECTION 10MG /ML, 2ML VIAL MEROPENEM 500MG & 1G VIAL (RESERVE) METRONIDAZOLE TABLET 200MG METRONIDAZOLE INJECTION 5MG /ML, 100ML BOTTLE METRONIDAZOLE VAGINAL TABLET 500MG NALIDIXIC ACID TABLET 500MG NITROFURANTOIN TABLET 100MG PIPERACILLIN/TAZOBACTAM VIALS 4.5MG (RESERVE) SPECTINOMYCIN INJECTION 2G TETRACYCLINE CAPSULE 250MG VANCOMYCIN INJECTION 500MG VIAL (RESERVE) Antileprosy Medicines CLOFAZIMINE TABLET 100MG DAPSONE TABLET 100MG Antituberculous Medicines ETHAMBUTOL TABLET 400MG ISONIAZID TABLET 100MG PYRAZINAMIDE TABLET 500MG RIFAMPICIN CAPSULE 300MG RIFAMPICIN300MG/ISONIAZID 150MG TABLET STREPTOMYCIN INJECTION 1G/VIAL Antifungal Medicines AMPHOTERICIN B INJECTION 50MG VIAL (RESERVE) CLOTRIMAZOLE CREAM 1%, 20G TUBE CLOTRIMAZOLE PESSARIES 100MG FLUCONAZOLE CAPSULE 50MG & 150MG (C ) GRISEOFULVIN TABLET 500MG NYSTATIN SUSPENSION 100,000IU / ML, 30ML BOTTLE Page 4 Antimalarials CHLOROQUINE SULPHATE TABLET 200MG (150MG BASE) ) MEFLOQUINE HCL TABLET 250MG PYRIMETHAMINE TABLET 25MG QUININE HYDROCHLORIDE INJECTION 300MG/ML, 2ML AMPOULE QUININE SULPHATE TABLET 300MG Antiviral (Antiherpes) Medicines ACYCLOVIR TABLET 200MG ACYCLOVIR INJECTION 25MG/ML 10ML (RESERVE) ACYCLOVIR CREAM 5G Antipneumocystosis & Antitoxoplasmosis Medicines COTRIMOXAZOLE INJECTION 96MG/ML, 5ML AMPOULE COTRIMOXAZOLE TABLET 960MG PYRIMETHAMINE TABLET 25MG SULPHADIAZINE TABLET 500MG (C ) ANTIMIGRAINE MEDICINES For Treatment of Acute Attack ERGOTAMINE TARTRATE TABLET 1MG PARACETAMOL TABLET 500MG For Prophylaxis PROPANOLOL TABLET 40MG PIZOTIFEN TABLET 0.5MG ( C) ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE MEDICINES Immunosuppressive Medicines AZIATHROPINE TABLET 50MG ( C) CYCLOSPORIN CAPSULE 100MG; 50MG;25MG ( C) MYCOPHENOLATE MOFETIL TABLET 500MG ( C) HYDROXYCHLOROQUINE TABLET 200MG ( C) Cytotoxic Medicines CISPLATIN INJECTION, 50MG VIAL CYCLOPHOSPHAMIDE INJECTION, 500MG VIAL DOXORUBICIN INJECTION, 10MG/5ML & 50MG/25ML VIALS FOLINIC ACID 50MG 5ML VIAL FLUOROURACIL INJECTION 50MG/ML, 10ML AMPOULE HYDROXYUREA CAPSULE 500MG METHOTREXATE INJECTION, 50MG VIAL METHOTREXATE TABLET 2.5MG VINCRISTINE INJECTION, 5MG VIAL Adjuvant Treatment FILGRASTIM 30IU PREFILLED SYRINGES GRANISETRON 3MG AMPS Page 5 Hormones and Antihormones BICALUTAMIDE 50MG TABLET CYPROTERONE ACETATE 50MG TABLET (C ) DEXAMETHASONE 4MG/ML METHYLPREDNISOLONE SUCCINATE INJECTION 120MG VIAL PREDNISOLONE TABLET 20MG (C ) TAMOXIFEN TABLET 10MG (C ) LETROZOLE TABLET 2.5MG (C ) ANTIPARKINSON MEDICINES BENZHEXOL TABLET 2MG LEVODOPA100MG + CARBIDOPA 25MG TABLET ROPINIROLE TABLET 1MG & 2MG (C ) MEDICINES AFFECTING THE BLOOD Anticoagulants and Antagonists ETAMSYLATE INJECTION 125MG /ML, 2ML AMPOULE FRAXIPARINE INJECTION 0.3ML/0.6ML PREFILLED SYRINGE HEPARIN SODIUM INJECTION 5,000IU/ML, 5ML VIAL (IV/SC) PROTAMINE SULPHATE INJECTION 10MG / ML, 5ML AMPOULE TRANEXAMIC ACID INJECTION 100MG/ML, 5ML AMPOULE VITAMIN K (PHYTOMENADIONE) INJECTION 10MG /ML, 1ML AMPOULE; PAED 1MG/0.5ML AMPOULE WARFARIN TABLET 3MG /5MG Blood Products & Plasma Substitutes FACTOR VIII FRACTION, DRIED INJECTION 250 UNITS (+/- 10%) BOTTLE OXYPOLYGELATINE 5.5%, 500ML BOTTLE HUMAN PLASMA ALUBUMIN 20% 100ML Antianaemic Medicines FERROUS SULPHATE TABLET 200MG (65MG IRON) FERROUS SULPHATE SYRUP 60MG (12MG IRON)/5ML, 200ML BOTTLE FERROUS SULPHATE AND FOLIC ACID TABLET 200MG + 400MCG FOLIC ACID TABLET 5MG HYDROXOCOBOLAMIN (VITAMIN B12) INJECTION 1MG/ML, 1ML AMPOULE METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 50MCG / 75MCG/150MCG PREFILLED SYRINGE (MICERA) (C ) IRON SUCROSE INJECTION 20MG/ML, 5ML AMPOULE IV (C ) IRON DEXTRAN 50MG/ML 2ML CARDIOVASCULAR DRUGS Antianginal Medicines ATENOLOL TABLETS 50MG ISOSORBIDE DINITRATE INJECTION 1MG /ML, 10ML AMPOULE ISOSORBIDE DINITRATE TABLETS, SUBLINGUAL 5MG ISOSORBIDE DINITRATE S/R TABLETS 20MG Page 6 Antiarrhythmic Medicines ADRENALINE INJECTION 0.1MG/ML, 1ML AMPOULE AMIODARONE HCL INJECTION 50MG /ML, 3ML AMPOULE AMIODARONE HCL TABLET 200 MG ( C) ATENOLOL TABLET 50MG DIGOXIN INJECTION 0.5MG DIGOXIN TABLET 0.25MG ISOPRENALINE INJECTION 1MG/ML, 2ML AMPOULE LIGNOCAINE HCL IV INJECTION 20MG /ML, 5ML SYRINGE VERAPAMIL INJECTION 2.5MG /ML, 2ML AMPOULE VERAPAMIL TABLET 40MG Antihypertensive Medicines AMLODIPINE TABLET 5MG & 10MG ATENOLOL TABLET 50MG BENDROFLUAZIDE TABLET 5MG SCORED CLONIDINE TABLET 100MCG ( C) DILTIAZEM TABLET 60MG HYDRALAZINE TABLET 25MG LABETALOL HCL INJECTION 5MG /ML, 20ML AMPOULE LABETALOL TABLET 100MG ( C) LISINOPRIL TABLET 5MG & 20MG LOSARTAN TABLET 50MG METHYLDOPA TABLET 250MG PROPANOLOL TABLET 40MG Medicines used in Heart Failure CARVEDILOL TABLET 6.25MG; 12.5MG; 25MG ( C) DIGOXIN ELIXIR 50MCG /ML, 60ML BOTTLE (C) DIGOXIN INJECTION 250MCG /ML, 2ML AMPOULE DIGOXIN TABLET 0.25MG FUROSEMIDE TABLET 40MG FUROSEMIDE INJECTION 10MG/ML 2ML DOPAMINE INJECTION 40MG/ML, 5ML AMPOULE LISINOPRIL TABLET 5MG/20MG LOSARTAN TABLET 50MG Medicines used in Benign Prostatic Hyperplazia ALFAZOSIN TABETS 2.5MG & 10MG
Load more

Recommended publications
  • Pharmaceutical Powder Compressibility – a Science-Based Approach
    Pharmaceutical powder compressibility – a science-based approach Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Nicolaos D.Gentis aus Egrigoros (Chios) Griechenland Oberkulm (AG) Schweiz Basel, 2012 Approval Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Matthias Hamburger und PD Dr. Gabriele Betz und Prof. Dr. Thierry F. Vandamme Basel, den 21. Februar 2012 Prof. Dr. Martin Spiess Dekan 2 Dedicated to my parents with love, appreciation and respect 3 Σωκράτης ―I know one thing, that I know nothing‖ Socrates c. 469 BC – 399 BC 4 Acknowledgements The work for this PhD thesis was carried out in the Industrial Pharmacy Lab, Department of Pharmaceutical Sciences, University of Basel and at the facility of Natoli Engineering Inc. in Saint Louis, Missouri (USA). I would like to express my appreciation and sincere gratefulness to PD Dr. Gabriele Betz for giving me the opportunity to do a PhD under her excellent supervision with essential, continuous support, guidance and brilliant, positive motivation. I would like to thank Prof. Dr. Matthias Hamburger for accepting to be my Faculty Responsible and for the support. My appreciation goes also to Prof. Dr. Thierry F. Vandamme for accepting to assume the co-referencing of this PhD thesis. At this point I would like to thank all former Industrial Pharmacy Research Group members for the unique support and for the great, crazy working atmosphere in the laboratory. Especially I would like to thank Mr. Branko Z. Vranic for his great collaboration and support in the research work of project 2 in this thesis.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • A Comparative Efficacy of Propacetamol and Ketorolac in Postoperative Patient Controlled Analgesia
    Korean J Pain 2015 July; Vol. 28, No. 3: 203-209 pISSN 2005-9159 eISSN 2093-0569 http://dx.doi.org/10.3344/kjp.2015.28.3.203 | Original Article | A Comparative Efficacy of Propacetamol and Ketorolac in Postoperative Patient Controlled Analgesia Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju, Korea Bong Ha Heo, Ji Hun Park, Jung Il Choi, Woong Mo Kim, Hyoung Gon Lee, Soo Young Cho, and Myoung Ha Yoon Background: Ketorolac has been used as a postoperative analgesia in combination with opioids. However, the use of ketorolac may produce serious side effects in vulnerable patients. Propacetamol is known to induce fewer side effects than ketorolac because it mainly affects the central nervous system. We compared the analgesic effects and patient satisfaction levels of each drug when combined with fentanyl patient-controlled analgesia (PCA). Methods: The patients were divided into two groups, each with n = 46. The patients in each group were given 60 mg of ketorolac or 2 g of propacetamol (mixed with fentanyl) for 10 minutes. The patients were then given 180 mg of ketorolac or 8 g of propacetamol (mixed with fentanyl and ramosetron) through PCA. We assessed the visual analogue pain scale (VAS) at the time point immediately before administration (baseline) and at 15, 30, and 60 minutes, and 24 hours after administration. Also, the side effects of each regimen and each patient’s degree of satisfaction were assessed. Results: There was a significant decline in the VAS score in both groups (P ＜ 0.05). However, there were no significant differences in the VAS scores between the groups at each time point.
    [Show full text]
  • Paracetamol Kabi Data Sheet
    NEW ZEALAND DATA SHEET 1 Paracetamol Kabi Solution for Infusion 10mg/mL 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Paracetamol Kabi solution for infusion contains 10 mg/mL of paracetamol (50 mL vial/bag contains 500 mg of paracetamol, 100 mL vial/bag contains 1 g of paracetamol). Paracetamol Kabi solution for infusion contains the excipients mannitol, cysteine hydrochloride, nitrogen (as protective gas), water for injections. 3 PHARMACEUTICAL FORM Paracetamol solution for infusion 10 mg/mL is a clear to slightly yellowish solution. Paracetamol is a white crystalline solid or powder chemically described as 4 – acetamidophenol. It is soluble in water (1 in 70), soluble in alcohol (1 in 7), acetone (1 in 13), glycerol (1 in 40), propylene glycol (1 in 9) and also soluble in solutions of the alkali hydroxides. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Paracetamol 10 mg/mL solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary. 4.2 Dose and method of administration The prescribed dose must be based on the patient’s weight. Unintentional overdose can lead to serious liver damage and death (see section 4.9 OVERDOSE). Healthcare providers are reminded that it is essential to follow both the weight-related dose recommendations and to consider individual patient risk factors for hepatotoxicity including hepatocellular insufficiency, chronic alcoholism, chronic malnutrition (low reserves of hepatic glutathione), and dehydration (see section 4.2 DOSE AND METHOD OF ADMINISTRATION – Hepatic Impairment). It is recommended that suitable oral analgesic treatment be substituted for Paracetamol solution for infusion as soon as the patient can be treated by the oral route (see section 4.3 CONTRAINDICATIONS).
    [Show full text]
  • (8) No. 1 March 2005 Alexandria Journal of Anaesthesia and Intensive Care 50
    Alexandria Journal of Anaesthesia and Intensive Care 49 Propacetamol Versus Placebo for Management of Acute Postoperative Pain After Elective Tonsillectomy in Children. Mahmoud A Nassef, MD*. Ashraf M Moustafa, MD**. Ashraf A Moussa, MD***. *Department of Anesthesia, Beni-Suef Faculty of Medicine, Cairo University **Department of Anesthesia, Menoufiya University ***Department of Anesthesia,Menoufiya Liver Institute, Menoufiya University ABSTRACT The analgesic efficacy and safety of propacetamol, an injectable prodrug of acetaminophen, was assessed versus placebo after elective tonsillectomy operation in children. Using a double-blind, randomized parallel group design, 70 children aged 6-12 years were included to evaluate the effect of a single iv infusion of 40 mg/kg propacetamol versus a single infusion of 100 ml normal saline ( placebo ) given at the recovery room. Analgesic efficacy was assessed on pain scores rated on a four-points verbal scale, a five-points visual scale ( faces ) and a four-points pain relief verbal scale; before administration ( T0 ) and 0.25, 0.5, 1, 2, 3, 4, 5 and 6 hours after the infusion. The global efficacy was rated on a five-point scale at the end of the study. Rescue medication was allowed freely and the time for re-medication as well as the occurrence of any side effects was recorded. Propacetamol was statistically superior to placebo on all assessment criteria. The global final efficacy evaluation demonstrated 12 patients in the propacetamol group with good and very good scores compared to only one patient in the placebo group. Rescue medication was used in 40% of patients in the propacetamol group versus 83% in the placebo group.
    [Show full text]
  • A Rare Case of Cerebral Venous Sinus Thrombosis (CVST) Induced by Norethisterone Enanthate: Report from a Medical University Hospital in Bangladesh
    Case Report Annals of Clinical Case Reports Published: 25 Jan, 2019 A Rare Case of Cerebral Venous Sinus Thrombosis (CVST) Induced by Norethisterone Enanthate: Report from a Medical University Hospital in Bangladesh Raknuzzaman1, Anis Ahmed1*, Masud Rana1, Kazi Jannat Ara1 and Dewan Md Emdadul Hoque1 1Department of Neurology, Bangabandhu Sheikh Mujib Medical University, Bangladesh 2Department of Epidemiology and Preventive Medicine, International Centre for Diarrhoeal Disease Research, Bangladesh Abstract Cerebral Venous Sinus Thrombosis (CVST) is a rare condition and the association between norethisterone enanthate and CVST in the literature has very seldom been reported. In this case report, a 22-year-old unmarried woman of Bangladesh presented with acute onset of headache and vomiting with history of oral intake of 5 mg norethisterone thrice daily during past 2 years for menstrual disorder. She had no history of seizure, visual disturbances, and neck stiffness, imbalance of gait and weakness of any limbs, any sensory complaints or any episode of unconsciousness during the course of illness. Bilateral papilloedema was present with more marked on left eye and serum homocysteine level was high. A brain CT scan, MRI and Magnetic Resonance Venogram (MRV) revealed thrombosed anterosuperior segment of superior sagittal sinus. She was diagnosed to have CVST due to norethisterone and was treated with low molecular weight heparin, followed by Rivaroxaban, Vitamin B12, Vitamin B6 and Folic acid. She made a complete recovery after one month of intake of rivaroxaban and withdrawn of norethisterone. Keywords: Cerebral venous sinus thrombosis; Norethisterone enanthate; Hyperhomocysteinemia; OPEN ACCESS Rivaroxaban *Correspondence: Introduction Anis Ahmed, Department of Neurology, Cerebral Venous Sinuses Thrombosis (CVST) is rare type of stroke with the annual incidence Bangabandhu Sheikh Mujib Medical ranging from 0.22 to 1.57 per 100,000 populations, affecting young individuals and mostly women University, Bangladesh, Tel: [1-3].
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    PHARMACEUTICALS volume 100 A A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 14-21 October 2008 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007).
    [Show full text]
  • Norethisterone Enanthate Has Neither a Direct Effect on the Testis Nor On
    European Journal of Endocrinology (2005) 152 655–661 ISSN 0804-4643 EXPERIMENTAL STUDY Norethisterone enanthate has neither a direct effect on the testis nor on the epididymis: a study in adult male cynomolgus monkeys (Macaca fascicularis) Aris Junaidi, C Marc Luetjens, Joachim Wistuba, Axel Kamischke, Ching-Hei Yeung, Manuela Simoni and Eberhard Nieschlag Institute of Reproductive Medicine of the University, Domagkstr. 11, D-48149 Mu¨nster, Germany (Correspondence should be addressed to E Nieschlag; Email:[email protected]) A Junaidi is now at the Faculty of Veterinary Medicine, Gadjah Mada University, Jl. Olah Raga, Yogyakarta, Indonesia Abstract Objective: Norethisterone enanthate (NETE) is evaluated in trials of hormonal male contraception. It has been speculated that progestins may exert their contraceptive effects not only by suppressing gon- adotropins but also by direct effects on male organs. NETE was given to monkeys in which endogen- ous gonadotropin secretion was suppressed by a gonadotropin releasing hormone (GnRH) antagonist, and replaced by human follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hCG). If NETE has a direct effect on spermatogenesis and/or epididymal function, some changes in testicular histology, sperm motility and/or morphology should occur soon after exposure to NETE. Methods: Fifteen adult intact male monkeys were grouped and treated for a 38-day period. Group I received GnRH antagonist, FSH, hCG and NETE while group II received a regime identical to group I without NETE and group III received only NETE and vehicle. Ejaculates, body weight, testicular biop- sies and volume, and hormones were evaluated. Results: There was a similar pattern of serum FSH and testosterone in groups I and II.
    [Show full text]
  • Guidance on Bioequivalence Studies for Reproductive Health Medicines
    Medicines Guidance Document 23 October 2019 Guidance on Bioequivalence Studies for Reproductive Health Medicines CONTENTS 1. Introduction........................................................................................................................................................... 2 2. Which products require a bioequivalence study? ................................................................................................ 3 3. Design and conduct of bioequivalence studies .................................................................................................... 4 3.1 Basic principles in the demonstration of bioequivalence ............................................................................... 4 3.2 Good clinical practice ..................................................................................................................................... 4 3.3 Contract research organizations .................................................................................................................... 5 3.4 Study design .................................................................................................................................................. 5 3.5 Comparator product ....................................................................................................................................... 6 3.6 Generic product .............................................................................................................................................. 6 3.7 Study subjects
    [Show full text]
  • Study on Sperm Suppression Using Norethisterone Enanthate and Testosterone Undecanoate
    Study on sperm suppression using Norethisterone enanthate and testosterone undecanoate Objectives Overall goal: and The study was designed to address the following primary objectives: Background 1. The rate of suppression of spermatogenesis induced by a regimen of NET-EN and TU administered every 8 weeks for up to 4 injection visits; and 2. The level of contraceptive protection provided by the continued administration of NET-EN and TU every 8 weeks for an efficacy period of up to 56 weeks. Background: The study was designed to evaluate whether the combination of a progestin, norethisterone enantate (NET-EN), and an androgen, testosterone undecanoate (TU), represents a safe and effective method of male fertility regulation. The study had 3 phases. The suppression phase was to initiate a status of decreased sperm count and activity to a level which would be considered as contraceptive. When this was reached it was sustained with subsequent injections in the efficacy phase, which would end after 56 weeks, or if a pregnancy occurs. After these, the participant was then placed in the recovery phase, and was observed until normal sperm counts and activity returns to normal. 487 participants were screened for eligibility, of which 167 were excluded. The remaining 320 were enrolled into the study, into the suppression phase. A total of 274 completed the suppression phase. Of these 8 discontinued before transitioning to the Efficacy phase, and were moved to recovery phase. A total of 266 transitioned to the efficacy phase, among which 111 completed 56 weeks follow up or until a pregnancy occurred. The remaining 155 were discontinued, either because of the stopping of the study by the sponsor (96), death (1, unrelated to the study), or for other reasons (58).
    [Show full text]